lncRNA-SNHG7 promotes the proliferation, migration and invasion and inhibits apoptosis of lung cancer cells by enhancing the FAIM2 expression

  • Authors:
    • Kelin She
    • Jun Huang
    • Huaping Zhou
    • Tonghai Huang
    • Guojun Chen
    • Jianxing He
  • View Affiliations

  • Published online on: September 19, 2016     https://doi.org/10.3892/or.2016.5105
  • Pages: 2673-2680
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

There is growing evidence that long non-coding RNAs (lncRNAs) are related to cancer development. In the present study, we found that the expression levels of lncRNA-SNHG7 mRNA and protein obviously increased in lung cancer tissues compared to adjacent non-cancerous tissues. Simultaneously, the expression levels of Fas apoptotic inhibitory molecule 2 (FAIM2) also increased in lung cancer tissues. In addition, lncRNA-SNHG7 was of positive relevance with FAIM2 in human lung cancer tissues. Silence of lncRNA‑SNHG7 by siRNA repressed the level of FAIM2 protein and suppressed cell proliferation, migration and invasion and accelerated apoptosis of A594 cells in vitro. Furthermore, silence of FAIM2 by siRNA generated a phenotype similar to silence of lncRNA-SNHG7 by siRNA. Therefore, our research showed that lncRNA-SNHG7 promotes the proliferation, migration and invasion, and inhibits apoptosis of lung cancer cells by enhancing the FAIM2 expression, suggesting that lncRNA-SNHG7 as a key regulator of gene expression, may be a promising therapeutic strategy for the treatment of lung cancer. It may improve the understanding of their biogenesis and function of lung cancer and further provide the theoretical fundamental basis for cancer pathogenesis and treatment.

Introduction

Lung cancer is one of the fastest-growing morbidity and mortality and the most serious threat tohuman health and life due to malignant tumors. Lung cancer is the most important cause of cancer-related deaths worldwide (13). It has been reported that more than 160,000 patients died of lung cancer which is more than from colon, prostate and even breast cancer, in the US during 2013 (4). At present, surgery, radiotherapy and chemotherapy have been used in the treatment of lung cancer. Nevertheless, the long-term survival rate is still very low (5). Research has also shown that most patients with lung cancer had been smoking in the US (6), and the genetic damage of lung cancer patients was mainly caused by smoking (7,8). The expression levels of mRNA and protein among thousands of genes can be used to analyze the molecular network among lung carcinogenesis (9,10). At present, epidermal growth factor receptor (EGFR) and echinoderm microtubule associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion genes have been used to detect lung cancer. Although many known genes and proteins have provided a large amount of information for the treatment of lung cancer, there are also a large number of unknown markers including non-coding RNAs (ncRNAs) which may be crucial regulators of cellular processes such as proliferation, gene regulation and apoptosis and may also serve as novel biomarkers for the treatment of lung cancer.

In recent years, the biomarker research has also focused on non-coding RNAs (ncRNAs), particularly lncRNAs, which are greater than 200 nt and most are transcribed by RNA polymerase (Pol) II/Pol I, small are transcribed by RNA Pol III (11), playing an important role in the regulation of gene expression (1215). In addition, there is growing evidence that lncRNA is related to cell cycle and cell differentiation (16), apoptosis (17,18) and chromatin remodeling (1921). It has also been shown that lncRNA expression are concerned with the development of various types of cancer, such as liver (22), lung (23) and breast cancers (24). For example, maternally expressed gene 3 (MEG3) is related to bladder cancer (25), and antisense non-coding RNA in the INK4 locus (ANRIL) is relative to plexiform neurofibromas (26). For lung cancer, recent studies predicted that MALAT1 was a critical regulator of lung cancer cells (27), SCAL1 promoted lung cancer by cigarette smoke (28), AK126698 produced drug resistance in lung cancer cells (29). Therefore, lncRNA is considered as an important regulating factor for gene expression, disease as well as cancers. However, the investigation into function and dysregulation of lncRNA in cancer has only just begun; increasing research is urgently needed to lead to a deeper understanding for the lncRNA regulatory network. In our study, we found that lncRNA-SNHG7 was obviously upregulated in lung cancer tissues compared to adjacent noncancerous tissues. Furthermore, silence of lncRNA-SNHG7 by siRNA suppressed cell proliferation, migration and invasion and accelerated apoptosis of A594 cells in vitro.

The present study showed, lncRNA-SNHG7 markedly inhibited apoptosis of A594 cells. Fas apoptotic inhibitory molecule 2 (FAIM2), as a 35 kDa membrane protein, is an anti-apoptotic protein conserved in evolution and known as the Lifeguard (LFG) family which is a distinct gene family of apoptotic-related genes (30). A previous study demonstrated that FAIM2 interacted with Fas upstream of Fas-associated death domain containing protein (FADD) and suppressed apoptosis (31). The high expression of FAIM2 enhanced resistance to Fas regulated apoptosis (32). Therefore, FAIM2 was used as apoptosis detection index. The present study found that the expression levels of FAIM2 also increased in lung cancer tissues. In addition, lncRNA-SNHG7 was of positive relevance with FAIM2 in human lung cancer tissues. Silence of FAIM2 by siRNA suppressed cell proliferation, migration, and invasion and accelerated apoptosis of A594 cells in vitro.

In the present study, we found that the expression levels of lncRNA-SNHG7 and FAIM2 obviously increased, and lncRNA-SNHG7 was of positive relevance with FAIM2 in lung cancer tissues. Silence of lncRNA-SNHG7 and silence of FAIM2 by siRNA suppressed cell proliferation, migration and invasion, and also accelerated the apoptosis of A594 cells in vitro, respectively. These results indicate that the lncRNA-SNHG7 network may lead to potential therapy for lung cancer in the future.

Materials and methods

Patients and clinical specimens

In the present study, we collected lung cancer and matched adjacent non-cancerous tissues samples (5 cm from the edge of the cancer as assessed by a pathologist) from patients who had undergone treatment for lung cancer between 2013 and 2015 at The First Affiliated Hospital of Southern Medical University, Guangzhou, China. The lung cancer histological diagnosis was confirmed according to the World Health Organization (WHO). Written informed consent was provided from each patient or her/his guardian. All tissue samples were washed with sterile phosphate-buffered saline (PBS) and was immediately saved at −80°C until use.

Cell lines

Three human lung cancer cell lines (H125, 95D and A594) and human bronchial epithelial cells (BEAS-2B) were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured according to the ATCC protocols, BEAS-2B cells were cultured in bronchial epithelial growth medium (BEGM; PromoCell GmbH, Heidelberg, Germany). H125, 95D and A594 were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA), and all the media contained 10% fetal bovine serum (FBS) and 100 U/ml penicillin and 1 µg/ml streptomycin (both from Invitrogen). Then, the cells were cultured in an incubator with 5% CO2 at 37°C.

siRNA transfection

According to the protocol, we performed the siRNA transfection using Lipofectamine 3000 (Thermo Fisher Scientific, Rockford, IL, USA). siRNA oligomers were synthesized by Gemma (Shanghai, China). lncRNA-SNHG7_siRNA sequence was: 5′-GCUGGAAUAAAGAGUAACAUU-3′; and FAIM2_siRNA sequence was: 5′-CUGGCUCCAUGCAGUUUAUUU-3′). A594 cells were seeded into 6-well plates (200,000 cells/well), and then transduced with control and lncRNA-SNHG7_siRNA or control and FAIM2_siRNA (final concentration 50 µM) using Lipofectamine RNAiMax (Life Technologies, Inc., Grand Island, NY, USA). Forty-eight hours after transfection, cells were used forthe tests.

RNA preparation and reverse transcription

According to the manufacturer's instructions, total RNA was extracted from cells or the lung cancer tissues samples by the TRIzol reagent (Invitrogen). RNA (1.0 µg) was used as a template to synthesize corresponding cDNA with random primers using a RevertAid First Strand cDNA synthesis kit (Thermo Fisher Scientific).

Quantitative real-time reverse transcription PCR (qRT-PCR) assay

qRT-PCR was completed using SYBR-Green PCR Master Mix kit (Takara, Shiga, Japan) and an ABI 7500 Real-Time PCR system (Applied Biosystems, Warrington, UK). The primers of endogenous housekeeping gene (GAPDH chosen as internal loading control), lncRNA-SNHG7 and FAIM2 were designed. The sequences of GAPDH primers were: 5′-GTCAGCCGCATCTTCTTTTG-3′ (sense) and 5′-GC GCCCAATACGACCAAATC-3′ (antisense). The sequences of lncRNA-SNHG7 primers were: 5′-GTTGGGGTGTTGGCATTCTTGTT-3′ (sense) and 5′-TGGTCAGCCTGGTCACTCTGG-3′ (antisense). The sequences of FAIM2 primers were: 5′-GGCGTGCTCTTCGTGCTTC-3′ (sense) and 5′-TGGCGTCGGTACCCATCA-3′ (antisense). The expression level of lncRNA-SNHG7 and FAIM2 mRNA was analyzed relative to the GAPDH mRNA level. All results are shown as the mean ± SD of three independent experiments.

Cell proliferation

Cell proliferation was measured using a Cell Counting Kit-8 (CCK-8 Kit; Beyotime Institute of Biotechnology, Jiangsu, China), transfected were seeded into 96-well plates at a density of 2×103 cells/well with 100 µl RPMI-1640 medium (with 10% FBS) and cultured for 24, 48 and 72 h, respectively. The 10 µl of CCK-8 solution was put into the well at each time point and incubated for 4 h at 37°C, and then the absorbance at 450 nm was measured using a microplate reader. Each experimental condition was detected in quintuplicates, and the experiments were repeated at least three times.

Flow cytometric analysis of apoptosis

The apoptotic cell death rate was analyzed by flow cytometry and double staining using propidium iodide (PI) and the Annexin V-FITC staining kit (BD Biosciences, San Diego, CA, USA) according to the manufacturer's instructions. A594 cells were digested with trypsin, dispersed, centrifuged, collected, washed with Dulbecco's modified Eagle's medium (DMEM) medium and cold PBS and resuspended with 1X binding buffer at a concentration of 1×106 cells/ml. PI (5 µl) and Annexin V-FITC were added into A594 cell buffer solution (1×105 cells) and incubated for 15 min at RT in the dark, and then 400 µl 1X binding buffer was put in each sample tube and analyzed by a BD FACSCalibur cytometer (BD Biosciences). Data were analyzed using FlowJo software version 8.8.6 (Tree Star Inc., Ashland, OR, USA). A594 cells transfected with NC-siRNA were used as the negative control (NC).

Migration and invasion assays

The migration and invasive capacity of the lung cancer cells in vitro were detected in 24-well Transwell cell culture chamber with 8-µm pores (both from Corning Costar Corp., Cambridge, MA, USA) according to the manufacturer's instructions. Cells were transfected with 50 µM lncRNA-SNHG7 siRNA, or control and FAIM2 siRNA for 48 h, and then 200 µl A594 cells (2.5×105/100 µl) were seeded in serum-free media to 8-µm pore cell culture inserts, and complete medium with 10% FBS was added to the lower chambers as a chemoattractant. Cells were incubated for 24 h at 37°C, and the cells with migration ability spread through the chamber. Paraformaldehyde (4%) was used to fix the cells and 0.1% crystal violet solution was used to stain the lower chamber cells. The cells above the upper surface that did not migrate were cleared with a cotton swab, but did not touch the lower layer of the membrane. The number of migratory cells was confirmed through counting five areas of constant size/well under the microscope using a 20× objective. For the invasion assays, the polycarbonate membrane of Transwell inserts were covered with 10 µl 1:3 diluted Matrigel (BD Biosciences), and then were dried at 37°C for 30 min. All experiments were completed in triplicate.

Western blot analysis

A594 cell homogenates were obtained with lysis buffer containing a protease inhibitor cocktail (P8340; Sigma-Aldrich, St. Louis, MO, USA), and lung cancer and matched adjacent non-cancerous tissue homogenates were obtained with RIPA buffer (Pierce/Thermo Fisher Scientific, Lafayette, CO, USA) containing a protease inhibitor cocktail. A BCA Protein Assay kit (Thermo Fisher Scientific) was used to measure the concentrations of total proteins. Proteins (30 µg) were separated using 8%, 12% Tris/glycine SDS/PAGE gels according to the molecular weight of the objective proteins, and then proteins were transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The PVDF membranes were blocked with 5% skim milk (BD Biosciences) in 1X Tris-buffered saline including Tween-20 (TBST) for 2 h at room temperature, the transferred membranes were incubated with primary antibodies with a proper dilution at 4°C overnight. Next day, the transferred membranes were washed with 1X Tris-buffered saline including Tween-20 three times, incubated with horseradish peroxidase-conjugated secondary antibodies with a proper dilution for 1 h at room temperature, and then washed with 1X Tris-buffered saline including Tween-20 three times, again. The experimental results were detected with the enhanced chemiluminescence (ECL) substrate kit and the enhanced chemiluminescence detection system (both from Amersham Biosciences, Piscataway, NJ, USA). The anti-human FAIM2 antibody (rabbit, 1:500; Sigma-Aldrich, Taufkirchen, Germany) which was used in the present study is a monoclone antibody. The rabbit anti-GAPDH monoclone antibody (1:4,000; Cell Signaling Technology, Beverly, MA, USA) was used as an internal control.

Statistical analysis

Statistical significance was analyzed using GraphPad (GraphPad Prism Software, La Jolla, CA, USA) and the SPSS 15.0 software [analysis of variance and Student's t-test or one-way analysis of variance (ANOVA)]. The data are presented as the means ± standard deviation (SD). P<0.05 was considered significant. P<0.05, P<0.01 and P<0.001.

Results

High expression of lncRNA-SNHG7 mRNA in lung cancer tissues and lung cancer cell lines

In order to investigate the expression of lncRNA-SNHG7 mRNA in lung cancer tissues, we adopted qRT-PCR assay to analyze the expression level of lncRNA-SNHG7 mRNA in lung cancer tissues relative to adjacent non-cancerous tissues. The results indicated that lncRNA-SNHG7 mRNA was obviously upregulated in lung cancer tissues compared to adjacent non-cancerous tissues (Fig. 1A). Furthermore, we analyzed the effect of lncRNA-SNHG7 mRNA in human bronchial epithelial cells (BEAS-2B) and three human lung cancer cell lines (H125, 95D and A594). qRT-PCR was used to measure the expression level of lncRNA-SNHG7 mRNA in the cell lines above. lncRNA-SNHG7 mRNA markedly increased in three human lung cancer cell lines (H125, 95D and A594) compared to human bronchial epithelial cells (BEAS-2B). Among the three human lung cancer cell lines, the expression level of lncRNA-SNHG7 mRNA in A594 cells was the most remarkable (Fig. 1B). Thus, we chose the A594 cells as target cells.

Silence of lncRNA-SNHG7 expression by siRNA inhibits proliferation, migration and invasion, and promotes apoptosis of A594 cells

A594 cells were transfected with negative control (NC) siRNAs and lncRNA-SNHG7 siRNA for 48 h, respectively. The expression effects of silence of lncRNA-SNHG7 mRNA expression by siRNA in A594 cells were measured by qRT-PCR. As shown in Fig. 2A, the expression of lncRNA-SNHG7 was markedly suppressed through lipofectin transfection compared to NC. CCK-8 assay was used to detected cell proliferation ability. As shown in Fig. 2B, the proliferation ability of A594 cells transfected with lncRNA-SNHG7 siRNA was significantly suppressed compared with the control group (P<0.05). Apoptotic cell death was detected by flow cytometric analysis with Annexin V-FITC and PI staining in A594 cells transfected with lncRNA-SNHG7 siRNA for 48 h. Knockdown of lncRNA-SNHG7 in A594 cells by siRNA accelerated apoptosis of A594 cells. As shown in Fig. 2C and D, the apoptosis cells percentage of A594 cells transfected with lncRNA-SNHG7 siRNA was 30.7%, while the control group was 12.4%. Thus, the apoptotic cell percentage of in A594 cells with knockdown of lncRNA-SNHG7 by siRNA increased 1.48 times. Transwell assay was used to detect migration and invasion abilities of A594 cells transfected with lncRNA-SNHG7 siRNA for 48 h. Knockdown of lncRNA-SNHG7 in A594 cells by siRNA decreased the ability of cell migration and invasion (Fig. 3A and B). Therefore, knockdown of lncRNA-SNHG7 in A594 cells inhibited the capacity of proliferation, migration and invasion and promoted the capacity of apoptosis of A594 cells.

lncRNA-SNHG7 physically interacts with FAIM2 in lung cancer clinical specimens and A594 cells

In our research, we demonstrated that lncRNA-SNHG7 inhibited the capacity of apoptosis of A594 cells. Therefore, FAIM2, an inhibitor of the Fas signaling pathway, was studied in lung cancer. In order to investigate the expression level of FAIM2 in lung cancer tissues, western blotting was used to detect the expression levels of FAIM2 proteins in human lung cancer and paired adjacent non-cancerous tissues from four random lung cancer patients. As shown in Fig. 4A, FAIM2 protein was higher expressed in lung cancer tissues. qRT-PCR was used to measure the expression levels of FAIM2 mRNA in human lung cancer tissues. FAIM2 mRNA was also higher expression in lung cancer tissues (Fig. 4B).

Furthermore, to investigate the correlation between lncRNA-SNHG7 and FAIM2 in human lung cancer tissues qRT-PCR results were analyzed. As shown in Fig. 4C, lncRNA-SNHG7 was of positive relevance with FAIM2 gene expression in human lung cancer tissues when A594 cells were transfected with FAIM2 siRNA for 48 h. The expression level of FAIM2 protein declined relative to NC (Fig. 4C). Therefore, lncRNA-SNHG7 increased the expression level of FAIM2 in lung cancer clinical specimens and A594 cells.

Silence of FAIM2 expression by siRNA inhibits proliferation, migration and invasion, and promotes apoptosis of A594 cells

Based on previous results that positive correlation between lncRNA-SNHG7 and FAIM2 gene expression was shown in human lung cancer tissues, in addition, lncRNA-SNHG7 can promote the expression level of FAIM2 in A594 cells. We further detected the effects of FAIM2 on A594 cell growth, migration, invasion and apoptosis. A594 cells were transfected with NC siRNAs and FAIM2 siRNA for 48 h, respectively. The expression effects of silence of FAIM2 mRNA and protein expression by siRNA in A594 cells were performed by qRT-PCR and western blotting. The expression of FAIM2 was markedly suppressed through transfecting with FAIM2 siRNA compared to NC (P<0.01) (Fig. 5A and B). The proliferation ability of A594 cells transfected with FAIM2 siRNA was measured by CCK-8 assay. The proliferation ability of A594 cells transfected with FAIM2 siRNA was significantly decreased compared with the control group (P<0.05) (Fig. 5C). Flow cytometric analysis was used to detect the apoptotic cell death of A594 cells transfected with FAIM2 siRNA with Annexin V-FITC and PI staining. We found that the apoptotic cell percentage of A594 cells transfected with FAIM2 siRNA was 32.3%, while the control group was 7.4%. Thus, the apoptotic cell percentage of A594 cells with knockdown of FAIM2 by siRNA increased 3.36 times (Fig. 5D and E). Thus, we indicated that silence of FAIM2 expression by siRNA increased apoptosis of A594 cells. Furthermore, we evaluated the ability of migration and invasion of A594 cells transfected with FAIM2 siRNA using Transwell assay. Silence of FAIM2 expression by siRNA in A594 cells reduced the ability of cell migration and invasion (Fig. 6A and B). Therefore, we indicated that knockdown of FAIM2 in A594 cells reduced the capacity of proliferation, migration and invasion and enhanced the capacity of apoptosis of A594 cells.

Discussion

The crucial results of the present study were that lncRNA-SNHG7 was highly expressed in lung cancer tissues relative to adjacent non-cancerous tissues. FAIM2 was also overexpressed in lung cancer tissues. lncRNA-SNHG7 was associated with FAIM2 and there was a positive correlation between them in lung cancer. Silence of lncRNA-SNHG7 by siRNA repressed the level of FAIM2 protein in A594 cells. Silence of lncRNA-SNHG7 and silence of FAIM2 by siRNA repressed the level of FAIM2 protein and suppressed cell proliferation, migration and invasion and accelerated apoptosis of A594 cells in vitro, respectively. Thus, our results showed that lncRNA-SNHG7 promotes the proliferation, migration and invasion and inhibits apoptosis of lung cancer cells by enhancing the FAIM2 expression and may be regarded as a potential therapeutic target for lung cancer.

Increasing number of studies has found that lncRNAs are connected with multiple genetic phenomena, such as transcriptional regulations, DNA methylation and chromatin remodeling (14,33,34). Increasing evidence indicates that lncRNAs are interacted with genes, proteins or chromatin remodeling to influence the expression levels of genes (35,36). LncRNAs which are generated in intronic, intergenic, antisense loci or overlapping regions play a great role in diverse gene regulatory functions (37,38). At present, numerous studies have demonstrated that lncRNAs are involved in tumor carcinogenesis since it can accelerate cell proliferation through controlling correlative proteins (3941). In the present study, we found that the expression levels of lncRNA-SNHG7 mRNA and protein obviously increased in lung cancer tissues compared to adjacent non-cancerous tissues. lncRNA-SNHG7 promoted the expression of FAIM2 protein and then inhibited A594 cell apoptosis. We also showed that silence of lncRNA-SNHG7 by siRNA suppressed cell proliferation, migration, and invasion and accelerated apoptosis of A594 cells in vitro. These results suggest that lncRNA-SNHG7 is an important molecule for tumor development and may become a potential biomarker for the treatment of lung cancer.

FAIM2, as a gene of the LFG family, will have very important effect in protecting cells against apoptosis by directly bonding the Fas receptor (31,42). It has been discovered that LFG was overexpressed in the mostly neuron and hippocampus cells (31). Recent studies have shown that expression of the FAIM2 was interrelated to high fat (43) and the different methylation levels of the FAIM2 promoter was markedly related to obesity (44). FAIM2 gene is associated with obesity (45), simultaneously, obesity is partly related to tobacco smoking which causes the development of cancer. However, the functional mechanism of FAIM2 is not entirely clear in lung cancer. In the present study, we have demonstrated that the expression level of FAIM2 mRNA increased in lung cancer tissues compared to adjacent non-cancerous tissues. Furthermore, positive correlation between lncRNA-SNHG7 and FAIM2 gene expression in human lung cancer tissues and silence of lncRNA-SNHG7 expression by siRNA reduced the expression of FAIM2 proteins in A594 cells. We also found that silence of FAIM2 expression by siRNA inhibited proliferation, migration and invasion and promoted apoptosis of A594 cells. These results suggest that FAIM2 also is an important molecule for tumor development.

In brief, the present study demonstrated that lncRNA-SNHG7 as an oncogene promoting proliferation, migration and invasion, and inhibiting apoptosis of lung cancer cells by enhancing the FAIM2 expression. This finding shows that lncRNA-SNHG7 is a momentous molecule for tumor progression and provides significant potential to develop new therapies to prevent or treat lung cancer.

References

1 

Parkin D, Whelan S, Ferlay J, Teppo L and Thomas D: Cancer Incidence in Five Continents. VIII. IARC Publications; pp. 1552002

2 

Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Malarcher AM, Schulman J, Epstein LA, Thun MJ, Mowery P, Pierce B, Escobedo L and Giovino GA: Methodological issues in estimating smoking-attributable mortality in the United States. Am J Epidemiol. 152:573–584. 2000. View Article : Google Scholar : PubMed/NCBI

7 

Organization WH: International statistical classification of diseases and related health problems. 1. World Health Organization; 2004

8 

Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Publications; 2004

9 

Granville CA and Dennis PA: An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol. 32:169–176. 2005. View Article : Google Scholar : PubMed/NCBI

10 

Meyerson M and Carbone D: Genomic and proteomic profiling of lung cancers: Lung cancer classification in the age of targeted therapy. J Clin Oncol. 23:3219–3226. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Bierhoff H, Schmitz K, Maass F, Ye J and Grummt I: Noncoding transcripts in sense and antisense orientation regulate the epigenetic state of ribosomal RNA genes. Cold Spring Harb Symp Quant Biol. 75:357–364. 2010. View Article : Google Scholar

12 

Wang KC and Chang HY: Molecular mechanisms of long noncoding RNAs. Mol Cell. 43:904–914. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Nagano T and Fraser P: No-nonsense functions for long noncoding RNAs. Cell. 145:178–181. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet. 10:155–159. 2009. View Article : Google Scholar : PubMed/NCBI

15 

Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, Garber M, Curran M, Onder T, Agarwal S, et al: Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 42:1113–1117. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Liu X, Li D, Zhang W, Guo M and Zhan Q: Long non-coding RNA gadd7 interacts with TDP-43 and regulates Cdk6 mRNA decay. EMBO J. 31:4415–4427. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Lakhotia SC: Long non-coding RNAs coordinate cellular responses to stress. Wiley Interdiscip Rev RNA. 3:779–796. 2012. View Article : Google Scholar : PubMed/NCBI

18 

Paralkar VR and Weiss MJ: A new 'Linc' between noncoding RNAs and blood development. Genes Dev. 25:2555–2558. 2011. View Article : Google Scholar : PubMed/NCBI

19 

Saxena A and Carninci P: Long non-coding RNA modifies chromatin: Epigenetic silencing by long non-coding RNAs. BioEssays. 33:830–839. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M and Xiong Y: Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene. 30:1956–1962. 2011. View Article : Google Scholar

21 

Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E and Chang HY: Long noncoding RNA as modular scaffold of histone modification complexes. Science. 329:689–693. 2010. View Article : Google Scholar : PubMed/NCBI

22 

Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, Zhu N, Zhou WP, Yang GS, Wang YZ, et al: Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology. 54:1679–1689. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Enfield KS, Pikor LA, Martinez VD and Lam WL: Mechanistic roles of noncoding RNAs in lung cancer biology and their clinical implications. Genet Res Int. 2012:7374162012.PubMed/NCBI

24 

Piao HL and Ma L: Non-coding RNAs as regulators of mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 17:33–42. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Ying L, Huang Y, Chen H, Wang Y, Xia L, Chen Y, Liu Y and Qiu F: Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Mol Biosyst. 9:407–411. 2013. View Article : Google Scholar : PubMed/NCBI

26 

Dereure O: Role of non-coding RNA ANRIL in the genesis of plexiform neurofibromas in neurofibromatosis type 1. Ann Dermatol Venereol. 139:421–422. 2012.In French. View Article : Google Scholar : PubMed/NCBI

27 

Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al: The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013. View Article : Google Scholar

28 

Thai P, Statt S, Chen CH, Liang E, Campbell C and Wu R: Characterization of a novel long noncoding RNA, SCAL1, induced by cigarette smoke and elevated in lung cancer cell lines. Am J Respir Cell Mol Biol. 49:204–211. 2013. View Article : Google Scholar : PubMed/NCBI

29 

Yang Y, Li H, Hou S, Hu B, Liu J and Wang J: The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One. 8:e653092013. View Article : Google Scholar : PubMed/NCBI

30 

Hu L, Smith TF and Goldberger G: LFG: A candidate apoptosis regulatory gene family. Apoptosis. 14:1255–1265. 2009. View Article : Google Scholar : PubMed/NCBI

31 

Somia NV, Schmitt MJ, Vetter DE, Van Antwerp D, Heinemann SF and Verma IM: LFG: An anti-apoptotic gene that provides protection from Fas-mediated cell death. Proc Natl Acad Sci USA. 96:12667–12672. 1999. View Article : Google Scholar : PubMed/NCBI

32 

Beier CP, Wischhusen J, Gleichmann M, Gerhardt E, Pekanovic A, Krueger A, Taylor V, Suter U, Krammer PH, Endres M, et al: FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. J Neurosci. 25:6765–6774. 2005. View Article : Google Scholar : PubMed/NCBI

33 

Mercer TR and Mattick JS: Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol. 20:300–307. 2013. View Article : Google Scholar : PubMed/NCBI

34 

Geisler S and Coller J: RNA in unexpected places: Long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 14:699–712. 2013. View Article : Google Scholar : PubMed/NCBI

35 

Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, et al: Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA. 106:11667–11672. 2009. View Article : Google Scholar : PubMed/NCBI

36 

Mattick JS and Gagen MJ: The evolution of controlled multi-tasked gene networks: The role of introns and other noncoding RNAs in the development of complex organisms. Mol Biol Evol. 18:1611–1630. 2001. View Article : Google Scholar : PubMed/NCBI

37 

Shamovsky I and Nudler E: Gene control by large noncoding RNAs. Sci STKE. 2006:pe402006. View Article : Google Scholar : PubMed/NCBI

38 

Kaikkonen MU, Lam MT and Glass CK: Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res. 90:430–440. 2011. View Article : Google Scholar : PubMed/NCBI

39 

Cooper C, Guo J, Yan Y, Chooniedass-Kothari S, Hube F, Hamedani MK, Murphy LC, Myal Y and Leygue E: Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides. Nucleic Acids Res. 37:4518–4531. 2009. View Article : Google Scholar : PubMed/NCBI

40 

Okamura D, Maeda I, Taniguchi H, Tokitake Y, Ikeda M, Ozato K, Mise N, Abe K, Noce T, Izpisua Belmonte JC, et al: Cell cycle gene-specific control of transcription has a critical role in proliferation of primordial germ cells. Genes Dev. 26:2477–2482. 2012. View Article : Google Scholar : PubMed/NCBI

41 

Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, et al: Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 29:742–749. 2011. View Article : Google Scholar : PubMed/NCBI

42 

Fernández M, Segura MF, Solé C, Colino A, Comella JX and Ceña V: Lifeguard/neuronal membrane protein 35 regulates Fas ligand-mediated apoptosis in neurons via microdomain recruitment. J Neurochem. 103:190–203. 2007.PubMed/NCBI

43 

Yoganathan P, Karunakaran S, Ho MM and Clee SM: Nutritional regulation of genome-wide association obesity genes in a tissue-dependent manner. Nutr Metab. 9:652012. View Article : Google Scholar

44 

Wu L, Zhao X, Shen Y, Zhang MX, Yan Y, Hou D, Meng L, Liu J, Cheng H and Mi J: Promoter methylation of fas apoptotic inhibitory molecule 2 gene is associated with obesity and dyslipidaemia in Chinese children. Diab Vasc Dis Res. 12:217–220. 2015. View Article : Google Scholar : PubMed/NCBI

45 

Boender AJ, van Rozen AJ and Adan RA: Nutritional state affects the expression of the obesity-associated genes Etv5, Faim2, Fto, and Negr1. Obesity. 20:2420–2425. 2012. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November-2016
Volume 36 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
She K, Huang J, Zhou H, Huang T, Chen G and He J: lncRNA-SNHG7 promotes the proliferation, migration and invasion and inhibits apoptosis of lung cancer cells by enhancing the FAIM2 expression. Oncol Rep 36: 2673-2680, 2016
APA
She, K., Huang, J., Zhou, H., Huang, T., Chen, G., & He, J. (2016). lncRNA-SNHG7 promotes the proliferation, migration and invasion and inhibits apoptosis of lung cancer cells by enhancing the FAIM2 expression. Oncology Reports, 36, 2673-2680. https://doi.org/10.3892/or.2016.5105
MLA
She, K., Huang, J., Zhou, H., Huang, T., Chen, G., He, J."lncRNA-SNHG7 promotes the proliferation, migration and invasion and inhibits apoptosis of lung cancer cells by enhancing the FAIM2 expression". Oncology Reports 36.5 (2016): 2673-2680.
Chicago
She, K., Huang, J., Zhou, H., Huang, T., Chen, G., He, J."lncRNA-SNHG7 promotes the proliferation, migration and invasion and inhibits apoptosis of lung cancer cells by enhancing the FAIM2 expression". Oncology Reports 36, no. 5 (2016): 2673-2680. https://doi.org/10.3892/or.2016.5105